Paxis Pharmaceuticals

Paxis Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in the reformulation of established oncology therapeutics to improve their safety and efficacy profiles. The company's primary focus is the development of PX-102, a nanoparticle formulation of paclitaxel that is free from toxic solvents such as Cremophor EL and polysorbate 80, which are known to cause severe hypersensitivity reactions. By eliminating these surfactants, Paxis aims to provide a more tolerable treatment option for patients with various solid tumors, including breast and lung cancers. Although the company successfully advanced PX-102 into Phase 1 clinical trials, it has shown limited public activity and corporate updates in recent years.